

| Prescriber Information | | | | | | | |
|------------------------|--|-------|----|-----------------------------------|----|------|------|
| Prescriber Name: | | | MD | DO | NP | PA | NPI: |
| Office Contact: | | | | Practice Name / Collaborating MD: | | | |
| Address: | | City: | | State: | | Zip: | |
| Phone: | | Fax: | | | | | |

| Patient Information • PLEASE SEND COPY OF INSURANCE CARD | | | | | | | | |
|--|--|--|-------|----------------|----------|--------------|---------|---------------|
| Patients Name: | | Last 4 Digits of SS#: | | DOB: / / | Sex: M F | Weight: | Height: | Diabetic? Y N |
| Address: | | | City: | | State: | | Zip: | |
| Home Phone: | | Work/Cell: | | HIPAA Contact: | | Emergency #: | | |
| Interpreter Needed? Y N | | Allergies: Y N If Yes, list allergies: | | | | | | |

| Insurance Information | | | | | |
|-----------------------|--|------------|-----------------------|------|------|
| Primary Insurance: | | Policy ID: | Group #: | BIN: | PCN: |
| Policyholder Name: | | | Policyholder DOB: / / | | |

| Clinical Information • PLEASE SEND COPY OF MEDICAL AND PRESCRIPTION INSURANCE CARDS, PROGRESS NOTES AND LAB REPORTS, SUPPORTING DIAGNOSIS, CO-MORBIDITIES AND LAB VALUES | | | | | | | | |
|--|--|--|--|------------------------|--|----------------------|----|---------------------|
| ICD-10 Code: | | Weight: lb / kg | | Height: in / cm | | BSA | m2 | Diagnosis Date: / / |
| Current Scr or current GFR | | ml/min | | Confirmed Mutations: | | | | |
| Prior Therapy: | | Reason for Discontinuation of Therapy: | | Approximate Start Date | | Approximate End Date | | |

| Prescription Information | | | | |
|--|---|---|----------|---------|
| Medication | Dose/Strength | Sig | Quantity | Refills |
| RYDAPT® (midostaurin) | 25mg capsule | Take ___mg by mouth two times a day with food Other: | | |
| SORAFENIB (generic Nexavar®) | 200mg tablet | Take 400mg (2 tablets) by mouth two times a day without food Other: | | |
| SUNITINIB (generic Sutent®) | 12.5mg capsule 25mg capsule 37.5mg capsule 50mg capsule | Take ___mg by mouth once daily Take ___mg by mouth once daily for the first 4 weeks of a 6-week cycle Other: | | |
| TAFINLAR® (dabrafenib) | 50mg capsule 75mg capsule 10mg tablet for oral suspension | Take 150mg (2 capsules) by mouth two times a day without food (at least 1 hour before or 2 hours after a meal) Take ___mg by mouth two times a day without food (at least 1 hour before or 2 hours after a meal) Other: | | |
| TEMODAR® (temozolomide) | 5mg capsule 20mg capsule 100mg capsule 140mg capsule 180mg capsule 250mg capsule | | | |
| VIJOICE® (alpelisib) | 50mg tablet 125mg tablet 200mg tablet | Take ___mg by mouth once daily with food | | |
| VOTRIENT® (pazopanib) | 200mg tablet | Take ___mg by mouth once daily without food (at least 1 hour before or 2 hours after a meal) Other: | | |
| XELODA® (capecitabine) | 150mg tablet 500mg tablet | | | |

By signing this form and utilizing our services, you are authorizing Meijer and its employees to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies.

| | | | |
|----------------------|------|----------------------|------|
| Prescriber Signature | Date | Prescriber Signature | Date |
|----------------------|------|----------------------|------|

Substitution Permitted

Dispense as Written

If brand is required, please write "DAW" in the box to the right.